Enhancement of nano titanium dioxide coatings by fullerene and polyhydroxy fullerene in the photocatalytic degradation of the herbicide mesotrione.

The surface modification of commercial TiO2 Hombikat (TiO2) using nanoparticles of fullerene C60 with tetrahydrofuran (THF-nC60), as well as fullerenol C60(OH)24 nanoparticles (FNP) was investigated in this study. Characterization of THF-nC60, FNP, TiO2, TiO2/THF-nC60, and TiO2/FNP was studied by using DES, ELS, TEM, SEM, DRS and BET measurements and their photoactivity has been examined on the mesotrione degradation under simulated sunlight. It was found that FNP in self-assembled nanocomposite TiO2/FNP increased negatively charge, as well as catalytic surface of TiO2. In addition, TiO2/FNP exhibits a shift of band gap energy to lower values compared to TiO2 and TiO2/THF-nC60. BET surface area has not showed significant differences among catalysts. Furthermore, it was found that the highest photoactivity was obtained for TiO2/FNP system. Besides, influence of different concentrations of electron acceptors (H2O2 and KBrO3), as well as scavengers on the kinetics of mesotrione removal in aqueous solution with/without TiO2 and FNP under simulated sunlight was investigated. Namely, addition of mentioned electron acceptors has resulted in higher mesotrione degradation efficiency compared to O2 alone. Besides, in the first period substrate degradation probably takes place via hydroxyl radicals and after 60 min of irradiation the reaction mechanism proceeds mainly via holes. The most efficient system for mesotrione degradation and mineralization were TiO2/7 mM KBrO3 and TiO2/7 mM KBrO3/40 µl FNP, respectively.

Metastatic Renal Cell Carcinoma to Jejunum: An Unusual Case Presentation.

The small intestine is a very uncommon and peculiar site for metastasis from renal cell carcinoma (RCC). We present a clinical presentation of insidious and unusual development of a jejunal metastasis while having stable disease in a remainder of metastatic sites, in a patient undergoing immunotherapy with nivolumab. Due to the extreme rarity of metastatic renal cell carcinoma to the lumen of the small bowel, it is easy to overlook and misdiagnose symptoms of this pathologic entity, particularly when the remainder of metastatic disease responds well to ongoing therapy.